Treatment pathways of lipid-lowering therapies in Germany 2016–2022
Changes in LLT were only observed in a minority of patients. BA and PCSK9i were switched more frequently than statins and ezetimibe. BA was discontinued earlier, and PCSK9i later than the other agents. Continued efforts to maintain long-term adherence and overcome therapeutic inertia are needed to realise the potential of available LLT with proven cardiovascular benefit.
Authors
- Beate Leppert (ORCID: https://orcid.org/0000-0002-5300-3331)
- Martin Schulz (ORCID: https://orcid.org/0000-0002-5876-7322)
- Ulrich Laufs (ORCID: https://orcid.org/0000-0003-2620-9323)
- Claudia Grellmann
- Julius L. Katzmann (ORCID: https://orcid.org/0000-0002-2457-1129)
- Irina Müller-Kozarez
Institutions
- Ingenieurgesellschaft Auto und Verkehr (Germany) (DE)
- Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie (DE)
- University Hospital Leipzig (DE)
- Klinik und Poliklinik für Neurologie (DE)
- Freie Universität Berlin (DE)
Publication Details
- Journal
- Clinical Research in Cardiology
- Published
- 2025-05-28
- DOI
- https://doi.org/10.1007/s00392-025-02686-5
- Citations
- 4
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 8.03
Funders
- Daiichi-Sankyo
- Daiichi Sankyo Europe